1. Von Willebrand factor (vWF) for the treatment and / or prophylaxis of a bleeding episode associated with thrombopathy induced by platelet-inhibiting substances. ! 2. vWF according to claim 1, where vWF is used or administered in combination with factor VIII as a combination of factor VIII / von Willebrand factor (FVIII / vWF). ! 3. vWF according to claim 1, where vWF or FVIII / vWF is administered to act as an antidote. ! 4. vWF according to claim 1, where vWF or FVIII / vWF is used or administered as a concentrate. ! 5. vWF according to claim 1, where vWF or FVIII / vWF is isolated from human blood plasma. ! 6. vWF according to claim 1, where vWF or FVIII / vWF is administered as a recombinant protein. ! 7. vWF according to claim 1, where vWF or FVIII / vWF is administered to a patient at a dose of 10 to 1000 units of vWF per kg body weight or 5-400 units of FVIII and 10-1000 units of vWF per kg body weight. ! 8. vWF according to claim 7, where vWF or FVIII / vWF is administered to a patient at a dose of 30 to 500 units of vWF per kg body weight or 20-200 units of FVIII and 30-500 units of vWF per kg body weight. ! 9. vWF according to claim 1, where the platelet inhibitory substance is a cyclooxygenase inhibitor, an ADP receptor inhibitor, or a combination thereof. ! 10. vWF according to claim 9, wherein the cyclooxygenase inhibitor is acetylsalicylic acid and wherein the ADP receptor inhibitor is a thienopyridine derivative, preferably clopidogrel or ticlopidine. ! 11. A method of preparing a medicament for the treatment and / or prophylaxis of a bleeding disorder associated with thrombopathy induced by platelet-inhibiting substances using a pharmaceutically effective amount of von Willebrand factor (vWF). ! 12. The method according to claim 11, where vWF is used or administered in combination with factor VIII as a combination of factor VIII / von Willebrand factor (FVIII / vWF). ! 13. The method according to claim 11, where vWF or FVIII / vWF is administered f
